Andreas Sutter
Senior Program Management Leader, Radiopharmaceuticals @Bayer
Signup · Get unlimited contacts
WORK HISTORY
Senior Program Management Leader, Radiopharmaceuticals @Bayer
Berlin, DE
Senior program management leader in oncology, driving strategic execution across early and late-stage portfolios with a focus on radionuclide therapies for prostate cancer and other tumor types.Key Responsibilities:Lead cross-functional initiatives from early development through global commercialization.Shape clinical and operational strategies to accelerate pipeline progress.Align medical, regulatory, and commercial teams around launch readiness and lifecycle planning.Translate complex program goals into actionable plans with measurable impact.Contribute to congress strategy, internal communications, and enterprise visibility.Committed to delivering innovation that improves patient outcomes and strengthens organizational performance.
EDUCATION
Universität Greifswald
Diploma, Cell/Cellular and Molecular Biology
The University of Freiburg
Degree in Pharmacy
Freie Universität Berlin
PhD, Cell/Cellular and Molecular Biology
Pharmaceutical Association Baden-Württemberg, Germany
Registration as a Pharmacist (Apotheker)
SKILLS
ABOUT ANDREAS SUTTER
As a results-driven pharmaceutical professional at Bayer, I have led key projects in oncology development and commercialization, as well as genetic toxicology, driving innovation in patient care. On the Oncology Global Strategic Marketing team for the GU Franchise, focusing on Prostate Cancer, my responsibilities included managing digital marketing campaigns, conducting competitive analyses, and aligning product development with market trends. These strategic initiatives enhance decision-making and optimize resource allocation for successful product launches.In early-stage oncology programs, I lead large international cross-functional teams in cell therapy, immuno-oncology, precision medicine, and radioligand therapies. I oversee project execution aspects like budgeting, timeline management, and quality assurance, setting industry standards for innovation. From 2013 to 2019, I was the Head of Genetic Toxicology at Bayer, managing up to 20 staff members in dual locations and pioneering in silico, in vitro, and in vivo methodologies to advance R&D and operational excellence.Educated with a PhD from the Free University of Berlin, I am well-versed in molecular and cellular biology, and pharmaceutical sciences. My commitment to the field is evidenced by multiple publications and patents.I am dedicated to advancing medical science and improving patient outcomes, focusing on the integration of scientific innovation with strategic business leadership to enhance healthcare.
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.